Biogen reports better than expected 3rd-qtr 2023 results

8 November 2023
biogen_big

US biotech major Biogen (Nasdaq: BIIB) today reported third quarter 2023 results and updated full year 2023 guidance that failed to impress investors, with its shares falling 4.7% to $235.34 in early trading’

Total revenue rose 1% year-over-year to $2.53 billion, but up 3% in constant currency, and beating forecasts for $2.23 billion, according to FactSet.

On an adjusted basis, earnings tumbled 9% year over year to $4.36 per share, also topping analysts’ views for $3.70.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology